Understanding Uterine Leiomyosarcoma: What I Learned After My Diagnosis
- Deborah Ann Martin
- 4 days ago
- 20 min read
Understanding Uterine Leiomyosarcoma Without Letting Statistics Define My Future
When I left the cancer center, I carried home a name I had never heard before: uterine leiomyosarcoma. Understanding uterine leiomyosarcoma became my first challenge because I barely knew how to pronounce it, much less understand what the diagnosis meant for my future.
The doctor had explained that it was a rare and aggressive cancer. She had told me that the lump on my back was connected to what was happening inside my abdomen. She had also warned me not to assume that I would be on the worst side of the survival statistics.
But I still did not truly understand what I had.
I had never known anyone with uterine leiomyosarcoma.
I did not know how it started, where it normally spread, how it was treated, or what my chances were of surviving it.
So, like many newly diagnosed patients, I went home and began searching Google.
The Beginning of the Google Searches
I typed the unfamiliar name into the search bar:
"Uterine leiomyosarcoma".
The results were frightening.
One website described it as rare.
Another called it aggressive.
One page gave one survival percentage, while another gave a different number. Depending on the source I found, I saw survival rates that seemed to range from approximately 17 to 24 percent for advanced disease.
I did not yet understand why the numbers varied.
I only understood that they were low.
The doctor had refused to give me a specific percentage because she did not want me to assume I would die. Now I was sitting at home reading numbers that seemed to confirm my worst fear.
The information was supposed to help me understand my cancer.
Instead, much of it frightened me.
Rare Cancer Research Can Feel Like Falling Down a Hole
When you search for a common cancer, you may find thousands of pages, large support organizations, treatment comparisons, patient stories, and clearly explained resources.
Searching for a rare cancer can feel different.
There may be fewer studies.
Some pages may be old.
One website may discuss all uterine sarcomas together, while another focuses only on uterine leiomyosarcoma. Some statistics may refer to localized cancer, while others refer to cancer that has spread. One source may use cancer stage, while another uses broader categories such as localized, regional, and distant.
I did not know how to separate any of that at first.
I was simply looking for an answer to one question:
“Am I going to live?”
Google could not answer that question.
What Is Uterine Leiomyosarcoma?
Uterine leiomyosarcoma, often shortened to uLMS, is a rare cancer that develops from the smooth muscle tissue of the uterus.
The uterus contains different types of tissue. The inner lining is called the endometrium. Most uterine cancers begin in that lining and are classified as endometrial cancers.
Uterine leiomyosarcoma begins in the muscular wall of the uterus, called the myometrium. Because it develops from muscle or connective tissue rather than the uterine lining, it is classified as a sarcoma.
That distinction matters.
Uterine leiomyosarcoma is not simply another name for the more common form of uterine cancer.
It behaves differently.
It may require different treatment decisions.
It should be evaluated by doctors with experience in gynecologic cancers and, when possible, sarcomas.
What Does the Name Mean?
The word "leiomyosarcoma" can be broken into parts.
"Leio" refers to smooth.
"Myo" refers to muscle.
"Sarcoma" refers to a cancer that begins in tissues such as muscle, fat, blood vessels, nerves, tendons, or other connective and supporting tissues.
In everyday language, uterine leiomyosarcoma is a cancer of the smooth muscle of the uterus.
Learning that helped me understand the long medical word.
It also raised another question.
I no longer had a uterus.
I had previously undergone a hysterectomy for what had been diagnosed as a benign fibroid.
Yet the cancer was called "uterine" leiomyosarcoma because that was believed to be where the cancer had originally begun.
Cancer can keep the name of its original site even after it moves to another area of the body.
For example, cancer that begins in the uterus and later appears in the back or abdomen is still uterine cancer. It does not become back cancer simply because a tumor is found there.
How Rare Is It?
Uterine sarcomas are uncommon, accounting for approximately 2% to 5% of all uterine malignancies. Leiomyosarcoma is one of the major types of uterine sarcoma.
That rarity creates challenges.
Many general physicians may see few or no cases during their careers.
There are fewer patients available for large clinical trials.
Treatment information may come from smaller studies or from research involving leiomyosarcomas arising in different parts of the body.
Patients may have difficulty finding local support groups containing someone with the same diagnosis.
Rare can feel lonely.
It can also make it harder to know whether the information found online truly applies to your situation.
Is Uterine Leiomyosarcoma the Same as a Fibroid?
No.
A uterine fibroid, also called a leiomyoma, is a benign growth of uterine smooth muscle.
Uterine leiomyosarcoma is malignant.
The names sound similar because both arise from smooth muscle tissue, but one is noncancerous and the other is cancer.
This difference was especially important in my story because my original uterine mass had been diagnosed as a benign fibroid.
Years later, I was told that I had uterine leiomyosarcoma.
Research does not generally support the idea that an ordinary benign fibroid routinely changes into leiomyosarcoma. Instead, leiomyosarcoma is usually considered a separate cancer that can sometimes resemble a fibroid before tissue is examined. I noted that uterine smooth muscle masses are often assumed to be benign fibroids because leiomyosarcoma is so uncommon.
That is one reason diagnosis can be difficult.
Imaging may show a uterine mass, but pathology is often necessary to determine exactly what type of tissue it contains.
Why Can It Be Mistaken for a Fibroid?
Fibroids are common.
Uterine leiomyosarcoma is rare.
When a woman has a uterine mass, a benign fibroid is statistically much more likely than a sarcoma.
The symptoms can also overlap.
Both may be associated with:
Pelvic pain
Pelvic pressure
Abnormal bleeding
An enlarged uterus or abdomen
A mass seen on imaging
Bladder or bowel pressure
The Foundation for Women’s Cancer reports that patients with uterine leiomyosarcoma may experience abnormal uterine bleeding, pelvic pain, or pelvic pressure, but those symptoms are not unique to cancer.
In my case, the recurrence did not announce itself with a long list of obvious symptoms.
I had pain in one specific place during intercourse.
That small symptom led me to request an ultrasound.
The ultrasound led to an MRI.
The MRI revealed the large abdominal masses.
The lump on my back led to the biopsy that finally gave the cancer a name.
Why Did I Have So Few Symptoms?
One of the hardest things for me to understand was how the tumors had grown so large without making me extremely ill.
I had gone to work.
I had continued living my ordinary life.
I thought my abdomen was becoming larger because I had gained weight.
I did not know several large masses were growing inside me.
Cancer symptoms depend on many factors, including the tumor’s location, size, rate of growth, and whether it presses on surrounding organs or nerves.
A mass can sometimes grow in an area with enough space that the body adjusts for a time. Symptoms may remain mild, vague, or easy to explain away until the tumor becomes large or affects a sensitive location.
That does not mean the patient failed to listen to her body.
Sometimes the body whispers.
Sometimes it gives a symptom that could easily have a harmless explanation.
Sometimes it does not provide a clear warning at all.
How Does Uterine Leiomyosarcoma Spread?
Uterine leiomyosarcoma can spread through the bloodstream to other parts of the body. It can also spread within the abdomen and pelvis, as well as through other pathways. The places it spreads are different from person to person.
That part of my cancer story became especially important after I learned what had happened during my hysterectomy.
My original uterine mass had been diagnosed as a fibroid. During my minimally invasive hysterectomy, my uterus and the mass were morcellated - cut into smaller pieces - and the tissue was not contained.
I did not understand what that meant at the time.
I did not even know what the word morcellation meant.
I learned about it only after I had been diagnosed with uterine leiomyosarcoma.
Why Morcellation Matters When the “Fibroid” Is Actually Cancer
When a presumed fibroid is actually an unsuspected uterine sarcoma, cutting that tissue into pieces can mechanically spread malignant tissue beyond the uterus.
The FDA specifically warns that morcellation of an unsuspected uterine sarcoma can spread cancerous tissue within the abdomen and pelvis and may decrease the likelihood of long-term survival.
That is different from saying that morcellation has been proven to cause every later tumor in every patient.
In my case, I cannot prove exactly how every cancer cell traveled from my original tumor to the places where cancer was later found.
What I do know is that my uterine tissue had been morcellated without containment, and I was later diagnosed with metastatic uterine leiomyosarcoma.
I eventually had three large tumors in my abdomen and another tumor on my back, along with additional growths that were benign.
Because uterine leiomyosarcoma can spread through the bloodstream, cancer cells can potentially travel from the original site to distant parts of the body. That is one reason metastatic disease can appear far from where the cancer began.
And because morcellation can mechanically disperse malignant tissue within the abdomen and pelvis, the possibility of an unsuspected cancer being morcellated is taken very seriously by the FDA.
This is why I believe uncontained morcellation is such an important part of my cancer story.
I cannot tell another woman that morcellation definitely caused my cancer to reach my back.
I can tell her what happened:
I had a uterine mass diagnosed as a fibroid.
My uterus and mass were morcellated without containment.
I later learned that I had uterine leiomyosarcoma.
Cancer was found in my abdomen and in a tumor on my back.
And I now live with the possibility of recurrence.
That experience changed the questions I believe women deserve to ask before a uterine mass is cut into pieces.
Why Did the Survival Numbers Vary?
The numbers I found online did not all match because websites may measure different things.
One page may report survival for all uterine sarcomas.
Another may report only uterine leiomyosarcoma.
One may describe stage I disease.
Another may combine all stages.
Some statistics are based on the traditional stage system, while others use the National Cancer Institute’s SEER categories:
Localized: Cancer remains near where it began.
Regional: Cancer has spread to nearby structures or lymph nodes.
Distant: Cancer has spread to distant parts of the body.
Older medical resources may also use patient data collected many years before the page was published.
A survival rate is necessarily backward-looking. Researchers must follow patients for years before calculating five-year outcomes.
That means the people included may have been diagnosed before newer drugs, improved scans, targeted therapies, molecular testing, or current treatment combinations were available.
Current Survival Statistics
The American Cancer Society currently reports these uterine leiomyosarcoma five-year relative survival rates for women diagnosed from 2015–2021:
Extent of Disease | 5-Year Relative Survival |
Localized | 61% |
Regional | 28% |
Distant | 13% |
All SEER stages combined | 38% |
These figures are group estimates. They do not predict exactly what will happen to one person.
An NCI professional summary uses a different staging approach and reports approximately 50 percent five-year survival for stage I disease, compared with approximately 0 to 20 percent for later stages. That difference illustrates why two trustworthy sources may show different numbers: they may use different patient groups, dates, stage categories, and methods.
When I was first researching, the figures I encountered were different from some numbers published today.
The internet was not necessarily lying to me.
The pages were often measuring different groups.
But without that explanation, the statistics felt confusing and absolute.
What Does “Relative Survival” Mean?
A five-year relative survival rate compares people with a particular cancer to people in the general population of similar age and other broad characteristics.
For example, a five-year relative survival rate of 20 percent does not mean every individual has exactly a 20 percent chance of being alive in five years.
It means that, as a group, people with that cancer were about 20 percent as likely as comparable people without it to be alive five years after diagnosis.
The number cannot account for every personal factor, including:
Exact tumor biology
Age
Overall health
Stage
Tumor size
Location of spread
Whether tumors can be removed
Response to treatment
Hormone receptor status
Genetic or molecular findings
New medications
Access to specialized care
Statistics describe the past experiences of groups.
They cannot see one person’s future.
Why Rare Cancer Statistics Need Context
Rare cancers have fewer patients available for study.
That can make estimates less precise.
Researchers may need to combine people with different stages, treatments, tumor characteristics, or sites of disease to produce useful data.
A rare-cancer survival percentage may also remain online for years after treatment options begin changing.
For example, the NCI reported in 2024 that a clinical trial involving advanced leiomyosarcoma found improved median survival when trabectedin was added to doxorubicin compared with doxorubicin alone. The combination is not necessarily appropriate for every patient, but the study demonstrates that treatment continues to develop after older survival data have already been collected.
A statistic may be accurate for the people included in the study and still be unable to reflect the future of treatment.
My Doctor’s Words Began to Make More Sense
As I read those numbers, I remembered what my doctor had told me.
“You never know which side of the statistics you are going to be on.”
At first, those words sounded like encouragement she gave every frightened patient.
Later, I understood the medical truth behind them.
Even when a survival rate is low, someone is represented on the surviving side of that number.
The statistic cannot tell you in advance which individual that will be.
I decided to take the cancer seriously without treating a percentage as my death sentence.
I would learn what I needed to learn.
I would ask questions.
I would pursue treatment.
I would prepare for hard possibilities.
But I would also leave room for the possibility that I could survive.
Years later, I reached my five-year mark.
The pages I read during those first searches could not see that part of my story.
How Is Uterine Leiomyosarcoma Diagnosed?
Diagnosis usually requires examination of tumor tissue by a pathologist.
Testing may include:
Physical examination
Ultrasound
MRI
CT scans
Biopsy
Surgery
Pathology review
Additional laboratory or molecular testing
Imaging can show that a mass exists, where it is located, and whether other suspicious areas are present.
Pathology helps identify the type of cancer.
In my case, the biopsy of the mass on my back provided the tissue that led to the uterine leiomyosarcoma diagnosis.
Because uLMS is rare, patients may ask whether the pathology has been reviewed by a specialist experienced in gynecologic sarcoma.
How Is It Treated?
Treatment depends on the stage, tumor locations, previous surgery, overall health, and other individual factors.
Possible treatments include:
Surgery
Chemotherapy
Radiation therapy
Hormone therapy for selected hormone-sensitive tumors
Targeted therapy
Clinical trials
Treatments intended to control symptoms or slow progression
Surgery is an important treatment when tumors can be removed. When the cancer has spread or returned, systemic treatments such as chemotherapy, targeted drugs, or hormone therapy may be considered.
There is no single treatment plan that applies to every patient with uterine leiomyosarcoma.
That is why a person newly diagnosed should be careful when reading another patient’s treatment story.
Their surgery, chemotherapy, or medication may not be appropriate for your disease.
How Can Genetic and Tumor Testing Personalize Cancer Treatment?
One of the things I learned later in my cancer journey was that not every cancer should be treated exactly the same way — even when two people have the same cancer diagnosis.
Doctors can use information about the patient and the tumor to help make more personalized treatment decisions.
This can include looking at:
My personal medical history
My family medical history
My age and overall health
Other medical conditions I have
Medications I already take
The characteristics of my tumor
Hormone receptors
Genetic changes in the tumor
Other molecular or biomarker findings
This type of approach is often called precision medicine or personalized medicine. The National Cancer Institute explains that precision medicine uses information about a person's genes, proteins, tumor, and other factors to help guide diagnosis and treatment.
Testing the Tumor Can Reveal Treatment Targets
Tumor testing, also called biomarker testing, genomic testing, or molecular profiling, looks for changes in the cancer cells that may affect how the cancer grows or how it responds to treatment.
Some cancers have specific genetic or molecular changes that can be targeted by certain medications.
That is where targeted therapy can come into the picture.
Targeted therapies are designed to interfere with specific proteins or other changes that help cancer cells grow, divide, or spread.
A tumor test may show that a cancer has a biomarker associated with a treatment that could potentially help.
It may also show that a particular treatment is unlikely to help, which can be just as important.
The goal is not simply to find more information.
The goal is to use the information to make better treatment decisions.
Genetic Testing Can Look at the Person, Too
There is another type of genetic testing that looks at the patient's own DNA rather than only the tumor.
This testing can look for inherited genetic changes that a person was born with.
A doctor's decision to recommend inherited genetic testing may take into account a person's personal and family medical history, including patterns of cancer in the family.
This type of testing can sometimes provide information that is important not only for the patient's treatment or cancer risk, but also for family members.
It is different from testing the tumor itself.
My Tumor Testing Became Important
In my own cancer journey, tumor testing became an important part of understanding what I was dealing with.
My cancer was found to be estrogen-receptor positive and progesterone-receptor positive, and testing also identified an ALK finding.
Those results gave my doctors additional information about my cancer and helped influence the treatments considered for me.
That was very different from simply knowing the name uterine leiomyosarcoma.
At the beginning, all I had was the diagnosis.
Later, I began learning that my cancer had its own characteristics.
Treatment Has to Consider the Whole Person
There is another part of personalized treatment that I think patients need to understand.
A drug might make sense based on the biology of a tumor, but that does not automatically mean it is the right drug for every patient.
Doctors also have to consider the person's overall health, medical history, other medications, and existing medical conditions.
Some medications can cause side effects that are particularly concerning for someone who already has another medical condition.
That means treatment decisions may involve balancing several questions:
Does the tumor have a target?
Is there a treatment that targets it?
Is that treatment likely to help?
What are the possible side effects?
Could those side effects make another medical condition worse?
Are there other medications I take that could interact with it?
Are there safer alternatives?
What is the goal of the treatment?
Is the treatment intended to eliminate cancer, control it, prevent or delay recurrence, or reduce symptoms?
These are not questions a genetic test can answer by itself.
They require a medical team to look at the whole person and the whole cancer picture.
Testing Does Not Guarantee a Targeted Treatment Will Work
This is important.
Finding a genetic change or biomarker does not guarantee that a particular medication will work.
NCI explains that even when testing identifies a potential treatment target, the treatment may not work. Cancer cells can differ within the same tumor, biomarkers can change over time, and other characteristics of the cancer or the patient's body can affect how well a treatment works.
So genetic and tumor testing is not a crystal ball.
It is another tool doctors can use to make more informed decisions.
What I Know Now
I wish I had understood earlier that cancer treatment could become much more individualized than simply:
“You have this cancer, so this is the drug you get.”
Instead, treatment can become a process of learning more about:
the patient + the tumor + the cancer's biology + the available treatments + the potential risks.
My treatment journey eventually became much more personalized than it was when I first heard the words uterine leiomyosarcoma.
I began with a cancer name.
Later, I learned about the individual characteristics of my cancer.
And that information helped my doctors make treatment decisions based on more than the name of the disease.
Why Seeing a Specialist Matters
Uterine leiomyosarcoma is not the most common type of uterine cancer.
Whenever possible, patients may benefit from evaluation by a gynecologic oncologist, sarcoma specialist, or treatment center with experience managing rare tumors.
The Foundation for Women’s Cancer recommends care from a gynecologic oncologist for cancers involving the uterus and other female reproductive organs.
A second opinion can be especially valuable when:
The cancer is rare
The pathology is uncertain
Major surgery is planned
Several treatment choices exist
The cancer has spread
A clinical trial may be available
The patient wants confirmation of the plan
Seeking a second opinion does not mean that you distrust your doctor.
It means you recognize that rare cancers can benefit from specialized experience.
Questions I Wish I Had Known to Ask
When I first began searching, I did not know enough to form the right questions.
A newly diagnosed patient might ask:
Where did my cancer originally begin?
What exactly did the pathology report say?
Has the pathology been reviewed by a sarcoma specialist?
What is the grade of the tumor?
What stage is the cancer?
Where has it spread?
Which tumors can be surgically removed?
What is the goal of surgery?
Will I need chemotherapy or radiation?
Should my tumor be tested for hormone receptors?
Is molecular or genomic testing recommended?
Should I see a sarcoma specialist?
Should I obtain a second opinion?
Are clinical trials available?
Which survival statistics most closely match my situation?
How old are those statistics?
What factors in my case are favorable?
What factors are concerning?
What happens next?
You may not receive every answer in one appointment.
Write the questions down.
Bring another person.
Ask the doctor to separate what is known from what is still uncertain.
How to Research Without Terrifying Yourself
Google is not automatically bad.
The problem is that a search engine does not know whether you need basic education, current treatment information, a research paper, or emotional reassurance.
It may show you the most frightening page first.
Begin With Trusted Sources
Start with:
National Cancer Institute
American Cancer Society
Foundation for Women’s Cancer
Society of Gynecologic Oncology
National Organization for Rare Disorders
Major academic sarcoma centers
Medical resources recommended by your oncology team
Check the Date
A page written many years ago may contain outdated treatment information or survival figures.
Look for the publication or review date.
Identify the Patient Group
Ask:
Is this about uterine leiomyosarcoma specifically?
Is it about all uterine sarcomas?
Is it about all leiomyosarcomas, regardless of where they started?
Is it localized or metastatic disease?
Which years were included?
How many patients were studied?
Do Not Compare Yourself With One Person Online
Patient stories can provide hope and practical support.
They cannot predict your outcome.
Two people with the same cancer name may have different stages, tumor features, treatments, health conditions, and responses.
Write Down Questions Instead of Searching All Night
When you find something frightening or confusing, add it to a question list for your doctor.
Internet research should help you communicate with your medical team.
It should not replace them.
Give Yourself a Stop Time
Searching at two in the morning rarely creates peace.
Choose a limited period for research.
Then step away.
Eat.
Rest.
Call someone safe.
Watch something ordinary.
Your brain needs time when it is not living inside cancer.
The Difference Between Information and Understanding
During my first searches, I collected information.
Understanding came later.
I learned that uterine leiomyosarcoma began in smooth muscle.
I learned that it was a sarcoma rather than the more common form of uterine cancer.
I learned that it could spread through the body.
I learned that it was rare and difficult to study.
I learned that the survival numbers depended heavily on stage and on which group a website was describing.
Most importantly, I learned that knowing the statistics was not the same as knowing my future.
What I Wish Someone Had Told Me
I wish someone had given me a short list of trustworthy websites before I went home.
I wish someone had explained why survival percentages varied.
I wish someone had told me that “uterine cancer” and “uterine leiomyosarcoma” were not interchangeable terms.
I wish someone had explained that rare cancer statistics often rely on smaller groups and older treatment periods.
I wish someone had warned me that searching late at night would not give me control over my future.
I also wish someone had said:
“You are allowed to learn about your cancer slowly.”
You do not need to understand every treatment, recurrence pattern, study, and statistic during the first week.
Start with the basics.
Learn the next step.
Let your knowledge grow as your medical team gives you more information.
My First Rare Cancer Research Checklist
Learn the Exact Diagnosis
Write down the complete cancer name and obtain the pathology report.
Confirm the Origin
Ask where the cancer began, especially when tumors are found in several places.
Learn the Stage and Grade
Do not rely on a general statistic before knowing which category best describes your disease.
Find a Specialist
Ask about gynecologic oncology and sarcoma expertise.
Request Pathology Review
Rare cancers may benefit from review at an experienced center.
Ask About Tumor Testing
Find out whether hormone receptor, genetic, or molecular testing could affect treatment.
Use Trustworthy Websites
Begin with recognized cancer and rare-disease organizations.
Date Every Statistic
Record the years of diagnosis included in the data, not only the date the webpage was updated.
Save Questions for the Doctor
Do not try to diagnose or treat yourself through internet searches.
Find Lived Experience Carefully
Patient communities can provide valuable understanding, but another person’s medical course is not your treatment plan.
Hope for Today
The first night you search a rare cancer can make your future feel very small.
You may see a percentage and believe your life has already been reduced to that number.
Mine had not.
I saw low survival figures.
I read the word aggressive.
I found very little information that felt hopeful.
Yet I reached five years.
That does not make the statistics meaningless.
It means they were never capable of telling my full story.
Use information to prepare yourself.
Use it to ask stronger questions.
Use it to understand why specialized care matters.
But do not use a population statistic to write the final chapter of a life that you are still living.
Frequently Asked Questions
What is uterine leiomyosarcoma?
It is a rare cancer that begins in the smooth muscle tissue of the uterus. It is a type of uterine sarcoma and differs from the more common cancers that begin in the uterine lining.
Is uterine leiomyosarcoma a type of fibroid?
No. Fibroids are benign smooth-muscle growths. Uterine leiomyosarcoma is malignant. The conditions can sometimes appear similar before tissue is examined.
Is it always possible to tell a fibroid from leiomyosarcoma before surgery?
Not always. Imaging and clinical findings may raise concern, but definitive identification often requires pathology.
Why do different websites show different survival rates?
They may use different years, staging systems, cancer types, patient groups, and definitions. Some report all stages together, while others separate localized, regional, and distant disease.
What is the current five-year survival rate?
The American Cancer Society currently reports approximately 61 percent for localized uLMS, 28 percent for regional disease, 13 percent for distant disease, and 38 percent for all stages combined, based on people diagnosed from 2015 through 2021. These figures cannot predict an individual outcome.
Does a low survival percentage mean I will die within five years?
No. A survival statistic describes outcomes among a group. It does not determine how long one individual will live.
Should I see a sarcoma specialist?
Because uLMS is rare, asking for consultation with a gynecologic oncologist or sarcoma specialist can be valuable, particularly for pathology review, surgery planning, advanced disease, recurrence, or clinical trial decisions.
Are treatments improving?
Research continues. New combinations, targeted treatments, hormone-based approaches, and clinical trials are being studied. The NCI reported improved survival in a 2024 trial using trabectedin with doxorubicin for advanced leiomyosarcoma compared with doxorubicin alone. That treatment is not appropriate for every patient, but it illustrates that care continues to develop.
Support on Your Journey
Rare cancer information can teach you what the disease is.
A person who has lived through it can help you understand what it feels like to carry that information.
Surviving Life Lessons was created to bring those two forms of support together.
Trustworthy medical information matters.
So does hearing from someone who remembers typing a rare cancer name into Google, reading a frightening percentage, and wondering whether she would live long enough to call herself a survivor.
Find Your Community
No one should have to face life's challenges alone. At Surviving Life Lessons, we believe in life survivors helping life strugglers. Explore our growing Community Groups to connect with others who understand your journey, share encouragement, and find hope through meaningful conversations. You'll also have the opportunity to introduce yourself and share your own story of overcoming. Your story matters. It may be the encouragement someone else needs to keep moving forward, reminding them that they are not alone and that hope is always possible.
Your Story Matters
We need your nice comments below! Your thoughts, experiences, and lessons learned might be exactly what someone else needs to hear today.
Drop a comment, Say Hello, and join the conversation.
Need More Personalized Support?
Everyone's journey is unique. If you're looking for personalized guidance, encouragement, or one-on-one support, explore our services to find the option that's right for you. We're here to help you take your next step with confidence and hope.
Helpful Resources for Your Journey
Explore our collection of books, journals, coloring books, and printable PDFs designed to encourage, inspire, and support you every step of the way.
References
National Cancer Institute — “Uterine Sarcoma Treatment (PDQ®)–Patient Version”\
National Cancer Institute — “Uterine Sarcoma Treatment (PDQ®)–Health Professional Version”\
National Cancer Institute — “Leiomyosarcoma”\
https://www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/rare-soft-tissue-tumors/leiomyosarcoma
American Cancer Society — “Survival Rates for Uterine Sarcoma”\
Foundation for Women’s Cancer — “Uterine Leiomyosarcoma”\
Society of Gynecologic Oncology — “Patient Resource – Rare Tumors: Uterine Leiomyosarcoma”\
National Organization for Rare Disorders — “Uterine Leiomyosarcoma”\
National Cancer Institute — “Combination Chemo Helps People with Leiomyosarcoma Live Longer”\
About the Author:
Deborah Ann Martin is the founder of Surviving Life Lessons, a published author, poet, speaker, and trainer with over 20 years of management experience across multiple industries. An MBA graduate, U.S. veteran, single mother, and rare cancer survivor, Deborah brings both professional expertise and lived experience to her writing on resilience, leadership, personal growth, and overcoming adversity. Her mission is to empower others with practical wisdom and real-life insight to navigate life’s challenges with strength and purpose.
.png){kind=small}
Comments